OncoMatch/Clinical Trials/NCT05465941
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Is NCT05465941 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pegylated SN-38 Conjugate PLX038 for platinum-resistant fallopian tube carcinoma.
Treatment: Pegylated SN-38 Conjugate PLX038 — This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Grade: high grade
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Exception: allowed if >4 weeks prior to registration
Chemotherapy =< 4 weeks prior to registration
Cannot have received: immunotherapy
Exception: allowed if >4 weeks prior to registration
Immunotherapy =< 4 weeks prior to registration
Cannot have received: radiotherapy
Exception: allowed if >4 weeks prior to registration
Radiotherapy =< 4 weeks prior to registration
Cannot have received: investigational therapy
Exception: allowed if >4 weeks prior to registration
Any other investigational therapy =< 4 weeks prior to registration
Lab requirements
Blood counts
Hemoglobin >= 8.0 g/dL; ANC >= 1500/mm^3; Platelet count >= 100,000/mm^3
Kidney function
Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula
Liver function
Total bilirubin >= 1.5 x ULN; ALT and AST <= 3 x ULN (<= 5 x ULN for patients with liver involvement)
Cardiac function
No myocardial infarction within 6 months; NYHA class IIB or better; QTc <= 480 msec (Fridericia) if prior doxorubicin (Doxil)
Hemoglobin >= 8.0 g/dL; ANC >= 1500/mm^3; Platelet count >= 100,000/mm^3; Total bilirubin >= 1.5 x ULN; ALT and AST <= 3 x ULN (<= 5 x ULN for patients with liver involvement); Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula; NYHA class IIB or better; QTc <= 480 msec (Fridericia) if prior doxorubicin (Doxil)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify